Treatment of Ataxia - Genetics Based
Explore cutting-edge genetic therapies for brain disorders, with a focus on antisense oligonucleotides (ASOs). This presentation details ASO mechanisms, preclinical development for Spinocerebellar Ataxia type 3 (SCA3), and promising ASO approaches for SCA1. Discover how ASOs target RNA and DNA, their efficient brain cell uptake, and ongoing challenges in widespread delivery.
Speaker: Ronald Buijsen
Level: Advanced
Publication year: 2026
Topics in this course: